162 results about "Ribonucleotide" patented technology

This disclosure provides compositions, pharmaceutical preparations, and methods relating to circular polyribonucleotides encoding the expression of Varicella-Zoster Virus immunogens.

In one aspect, the disclosed technology relates to nanopore sequencing with a polynucleotide including a plurality of ribonucleotides, wherein each ribonucleotide comprises a cyclic loop between two positions of the ribonucleotide, wherein the cyclic loop comprises a spacer or reporter moiety corresponding to the identity of the ribonucleotide, one or more linkers, and optionally one or more arresting constructs. The cyclic loop may be selectively cleaved in a ribose-mediated pathway to cause cleavage at the 5' P-O bond of the phosphate backbone.

The present disclosure relates to a modified 5'UTR derived from an alphavirus, such as the Venezuelan equine encephalitis virus (VEEV) wild-type 5'UTR sequence of SEQ ID NO 1 modified at least by a first nucleotide insertion, such as ribonucleotide insertion, between position 3 and position 4 of the corresponding wild-type 5'UTR sequence of SEQ ID NO 1, wherein the first nucleotide insertion is preferably guanine, adenine or uracil.

The present disclosure describes methods, kits, and systems for digesting polyribonucleotides. The methods involve selectively forming an oligonucleotide (e.g., DNA: RNA or RNA: RNA) duplex with a single-stranded target RNA, and then selectively cleaving the target RNA into smaller fragments using a sequence-specific nuclease that acts only on the RNA within the duplex. Additional sequence-specific ribonucleases can be used to provide additional cleavage of the target RNA at a predetermined site. By forming double strands to increase the availability of nuclease enzymes that can be used to cleave the single-stranded target RNA and to selectively control the location at which the target RNA is cleaved, the target RNA can be digested into fragments within a controllable size range that are optimal for polynucleotide analysis, such as by liquid chromatography and mass spectrometry.

This disclosure provides a vaccine including a peptide with the amino acid sequence of SEQ ID NO:1; a nucleotide having the sequence of SEQ ID NO:2; or a ribonucleotide having the sequence of SEQ ID NO:3. In certain embodiments, the vaccine further comprises a buffer and / or an adjuvant.

Disclosed herein is a modified ribonucleotide comprising a nucleoside comprising 2′-O-acetylated ribose, and polyribonucleotides comprising the same. Also provided herein are compositions comprising a polyribonucleotide of the present disclosure and methods of making and using the same.

The invention discloses a lysosome targeted degradation system based on a DNA phase separation aggregate as well as a preparation method and application of the lysosome targeted degradation system, and belongs to the technical field of biological medicine and nanotechnology. The lysosome targeted degradation system based on the DNA phase separation aggregate comprises an RNA-DNA tetrahedral framework with a cohesive end, the RNA-DNA tetrahedral framework is formed by self-assembly of a core chain and an edge chain through complementary base pairing, the edge chain is a DNA-RNA chimeric oligonucleotide chain, and the DNA-RNA chimeric oligonucleotide chain is a DNA-RNA chimeric oligonucleotide chain. One or more sections of RNA ribonucleotide sequences which can be specifically recognized and cut by RNase H enzyme are embedded in the sequence, and the tail end of the RNA ribonucleotide sequence is modified with a cohesive tail end for driving phase separation and a cell membrane anchoring group; the RNA-DNA tetrahedral framework is modified with an aptamer of a targeted membrane protein. After entering cells, the system is subjected to liquid-liquid phase separation in a lysosome acid environment through interaction of cohesive ends, a micron-sized large-size aggregate is formed in situ, the residence time of a nano-drug in the lysosome is prolonged, and efficient degradation of target membrane protein is realized.

The invention provides a chain-specific library preparation method and a high-throughput sequencing method for rapidly detecting multiple types of RNAs (Ribonucleic Acid). The method comprises the following steps: artificially adding poly A tails at 3'tail ends of multiple RNAs by utilizing poly A polymerase; meanwhile, a polydeoxythymine ribonucleotide primer with deoxyuracil is used for synthesizing single-stranded cDNA under the action of reverse transcriptase, obtained single-stranded cDNA molecules are subjected to a series of reactions and finally subjected to PCR amplification to obtain strand specific libraries of multiple types of RNA, and samples of the libraries can be subjected to computer sequencing.

The application discloses a single cell whole genome amplification sequencing method. The application comprises the following steps: 1) separating a single cell, adding a single cell lysis solution to sufficiently lyse the single cell and digest proteins combined on the genomic DNA; 2) using a Tn5 transposome with a specific adapter sequence to fragment the DNA, while adding adapters to both ends of the fragments; 3) after end repair, using a ribonuclease to cut modified ribonucleotide residues on the adapter sequence; 4) using the adapter sequence as a primer to linearly amplify the fragmented DNA by using a single primer PCR method; and 5) adding sequencing adapters to both ends of the DNA fragments by using a chain extension and PCR method to obtain a final sequencing library. The method disclosed by the application can amplify single cell whole genome DNA with high coverage, uniformity and fidelity, and simultaneously and accurately detect chromosomal copy number variation CNV and single nucleotide mutation SNV on a single cell genome.

To provide a food composition that does not contain animal-derived substances and that can be used as a food additive or flavoring to impart spice, umami, or meat seasoning to a food composition by utilizing fungi, yeast, and extracts of Ogataea pholymorpha. SOLUTION: The Ogataea polymorphic fungus yeast, extract, and biomass extract of the Ogataea polymorphic fungus of the present invention contain 0.03 to 3.1% w / w heme. They also contain 0.1 to 25% w / w amino acids. They also contain 0.1 to 2% w / w histidine. They are dissolved or formed by hydrolysis. The Ogataea polymorphic fungus of the present invention further contains proteins, amino acids, carbohydrates, and vitamins. They also contain glutathione. The present invention also relates to the production of recombinant heme proteins in methylotrophic yeast such as Ogataea polymorphic fungus. The Ogataea polymorphic fungus extract contains 0.007% or more 5' ribonucleotides. The 5' ribonucleotides are extracted from 5' GMP.

Disclosed herein is a modified ribonucleotide comprising a nucleoside comprising 2′-O-acetylated ribose, and polyribonucleotides comprising the same. Also provided herein are compositions comprising a polyribonucleotide of the present disclosure and methods of making and using the same.

Provided is a method for detecting a target nucleic acid by cleaving a non-natural sequence using a Cas12 protein, belonging to the technical field of biology. The Cas12 protein belongs to a Cas12a / Cas12b protein family. The non-natural sequence includes a chimeric sequence composed of a ribonucleotide and a deoxyribonucleotide. Such a sequence can be made into a probe for nucleic acid detection, and its detection effect is better than that of a conventional ssRNA probe, and in certain cases is equivalent to or even better than that of an ssDNA probe. Also provided is a system for detecting a target nucleic acid, including a chimeric sequence, a Cas12 protein and crRNA. The pre-amplification can increase the detection limit of the system to a single-molecule level. The Cas12-chimeric sequence detection system can be used not only on a microfluidic chip, but also in clinical testing. In summary, the coordinated use of the Cas12 protein and chimeric sequence optimizes the CRISPR / Cas12 detection system and expands the use of the Cas12a protein and non-natural sequence.

An aptamer composition is disclosed which has one or more oligonucleotides that include at least one of deoxyribonucleotides, ribonucleotides, derivatives of deoxyribonucleotides, derivatives of ribonucleotides, or mixtures thereof. The aptamer composition has a binding affinity for one or more cellular membrane glycoproteins selected from the group consisting of: intercellular adhesion molecule 1 (ICAM-1), low-density lipoprotein receptor (LDLR) family members, and cadherin-related family member 3 (CDHR3), preferably intercellular adhesion molecule 1 (ICAM-1), and is configured to reduce the binding of one or more human rhinoviruses to the intercellular adhesion molecule 1 (ICAM-1).

The present disclosure provides circular polyribonucleotides including a sequence including: a circularization element; a first spacer; an internal ribosome entry site (IRES) sequence; a sequence encoding a polypeptide; and a second spacer, where the sequence encoding the polypeptide has been codon-optimized to reduce the number of uracil ribonucleotides and / or reduce or remove TLR7- and TLR8-recognition motifs, and kits and compositions thereof. The present disclosure also provides methods of treating subjects in need thereof with the circular polyribonucleotides and compositions described herein.

The present invention provides a DNA-targeting RNA comprising a single-guide RNA (sgRNA) and a ribonucleotide sequence rich in adenine ribonucleotide, and its use in gene editing, and a method for improving the efficiency of sgRNA-mediated gene editing, comprising a step of adding a ribonucleotide sequence rich in adenine ribonucleotide at 3′ end of the sgRNA.

Disclosed are methods, systems, and computer readable media for predicting interactions for RNA sequences, including long noncoding RNA (IncRNA), which can be used, for example, as biomarkers. In an example method of predicting one or more binding sites between a ribonucleotide (RNA) sequence and a RNA binding protein, the method includes at a computing platform including at least one processor and memory: preparing sequence data for a plurality of overlapping RNA segments derived from a target sequence; inputting the sequence data for the plurality of overlapping RNA segments into a machine learning model trained to predict a probability of an interaction between a RNA sequence and a RNA binding protein occurring in a RNA sequence; outputting from the machine learning model one or more segments in the sequence data for the plurality of overlapping RNA segments falling above a probability threshold indicative of a region of interaction between a RNA sequence and a RNA binding protein; and predicting one or more binding sites between a RNA sequence and a RNA binding protein in the sequence data for the plurality of overlapping RNA segments derived from the target sequence based on the output from the model.

The present invention relates to an in vitro cell-free process for production of deoxyribonucleotides (DNAs) comprising at least one hairpin, corresponding DNA products and uses thereof, and oligonucleotides and kits useful in the process of the invention.

The present invention belongs to the technical field of biological detection, and provides a fluorescence biosensor for jointly detecting glutathione and ATP, comprising: a ligation probe L with nucleotide sequences shown in SEQ ID NO: 1-4, a padlock probe M, an ATP block strand, a reporter probe S, and Mg<supgt;2+< / supgt;, phi29 DNA polymerase, T4 DNA ligase, dNTP; the 5'-end of the padlock probe M is phosphorylated; the 8th and 9th positions of the ATP block strand are modified with disulfide bonds, and the 3'-end is modified with Inverted dT; the 13th and 14th positions of the reporter probe S are ribonucleotides; a fluorescence quenching group is modified before the 13th position, and a fluorescence reporting group is modified after the 14th position. The sensor of the present invention has the advantages of fast detection speed, low detection limit, high specificity, etc., realizes the joint detection of two target substances by one method, can make up for the defects and deficiencies of the existing detection methods, and realizes fast and accurate quantitative detection.

This invention discloses an electrochemical-fluorescence dual-mode biosensor for the detection of bladder cancer-related miRNA biomarkers and its application. The sensor is a homogeneous biosensor comprising a CRISPR / Cas13a system for specific recognition of target miRNAs, magnetic beads, multiple nucleic acid substrates, and one or more signal probes. The CRISPR / Cas13a system includes the Cas13a protein and crRNA with a complementary sequence to the miRNA. The magnetic beads bind to nucleic acid substrate 1, serving as the reaction substrate. After activation by the target miRNA, the CRISPR / Cas13a system trans-cleaves the ribonucleotide sites in the nucleic acid substrate 1 sequence bound to the magnetic beads. Magnetic separation of the magnetic beads and supernatant forms a dual-sensing circuit. The dual-sensing circuit reacts with different substrate nucleic acids and signal probes respectively, outputting electrochemical and fluorescence response signals, achieving single-shot dual-mode detection of the target miRNA.

The invention discloses a formula for keeping the re-fried crispness of rice crust and potatoes and a preparation method of the formula. The formula comprises raw materials and fresh potatoes; boiling ingredients, wherein the ingredients comprise water which submerges the amount of the potatoes in the container during boiling, and 2-3% of edible salt, 0.2-0.3% of monosodium glutamate and 0.03-0.05% of disodium 5 '-ribonucleotide which are blended into the water according to the concentration fraction; the slurry wrapping ingredient comprises the following components in percentage by mass: 10 to 20 percent of ice, 30 to 40 percent of water and 40 to 60 percent of slurry wrapping powder; the surfaces of the potatoes are fully soaked with the coating slurry when the potatoes are coated with the slurry. The rice crust potato semi-finished product prepared by the formula and the method limited by the invention can have the best crispness stability during re-frying after sale.

Provided are methods for preparing compounds and pharmaceutical compositions for treating Filoviridae viral infections. Provided are compounds, compositions and methods that are particularly useful for treating Marburg virus, Ebola virus and Campylobacter virus.

A comprehensive teaching aid system for genetic science at least including numerous (deoxy-) ribonucleotide models that can be assembled to form DNA / RNA single strands, or to form the beautiful DNA double helix structure when numerous adjacently and oppositely connected deoxynucleotide models are attached by magnets, tRNAs, and three different plates for DNA replication, mRNA transcription and protein synthesis respectively. The (deoxy-) nucleotide model includes a phosphate model, a (deoxy-) ribose model and a base model connected in sequence. Between two adjacently disposed (deoxy-) ribonucleotide models, a (deoxy-) ribose model is connected to a phosphate model in the head-to-tail fashion to form a detachable and flexible chain structure. The base model is laterally connected to the (deoxy-) ribose model, and two base models in two oppositely disposed deoxynucleotide models are flexibly and complementarily attached.

The present invention discloses an atomization drying device and method for preparing high-steady-state disodium 5'-ribonucleotide, relating to the technical field of atomization drying equipment, including a drying chamber and a mixing chamber. The mixing chamber is fixedly installed at the top of the drying chamber. A feed pipe is fixedly installed on the side wall of the mixing chamber. A partition plate I is fixedly installed inside the mixing chamber. A blanking pipe is fixedly installed on the partition plate I. Above the interior of the drying chamber, there is a nozzle seat. A spray head is mosaically and movably installed at the bottom of the nozzle seat. An air inlet pipe is installed on the side wall of the drying chamber. A plurality of air inlets are opened on the air inlet pipe. A partition plate II is fixedly installed inside the drying chamber. A plurality of inner plates are movably installed on the top of the partition plate II. The plurality of inner plates are connected by an elastic film. A wind guiding mechanism is arranged inside the drying chamber. A transmission mechanism is arranged between the drying chamber and the mixing chamber. The present invention can improve the uniformity of hot air distribution while facilitating the collection of the caked raw materials on the wind guiding plate and the inner plates.

A clustered regularly interspaced short palindromic repeat (CRISPR)-associated complex for adaptive antiviral defence (Cascade); the Cascade protein complex comprising at least CRISPR-associated protein subunits Cas7, Cas5 and Cas6 which includes at least one subunit with an additional amino acid sequence possessing nucleic acid or chromatin modifying, visualising, transcription activating or transcription repressing activity. The Cascade complex with additional activity is combined with an RNA molecule to produce a ribonucleoprotein complex. The RNA molecule is selected to have substantial complementarity to a target sequence. Targeted ribonucleoproteins can be used as genetic engineering tools for precise cutting of nucleic acids in homologous recombination, non-homologous end joining, gene modification, gene integration, mutation repair or for their visualisation, transcriptional activation or repression. A pair of ribonucleotides fused to FokI dimers may be used to generate double-strand breakages in the DNA to facilitate these applications in a sequence-specific manner.

The present invention relates to a method for tailing in vitro transcribed (IVT) messenger RNA (mRNA) containing modified ribonucleotides, the method comprising adding the IVT mRNA to a tailing polymerase in a reaction buffer containing up to 30 mM of an alkali metal salt and at least 5 mM of a reducing agent.